Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Michael E. Stokes' research focuses on the development of novel therapeutic agents, particularly small molecule inhibitors targeting key cellular pathways involved in disease progression. His work has explored inhibitors of the SARS-CoV-2 3CL protease for COVID-19 treatment and has significantly investigated the role of the eukaryotic initiation factor-2α kinase PERK in cancer metastasis and autoimmune diseases.
Stokes has published on PERK inhibitors, such as HC-5404, demonstrating their potential to block metastatic progression by limiting the survival of quiescent cancer cells and sensitize renal cell carcinoma models to antiangiogenic tyrosine kinase inhibitors. His research also extends to the clinical application and cost-effectiveness of medical treatments, including a comparative analysis of healthcare service utilization and costs for epilepsy management devices. He leads a research group and has a scholarly record indicated by an h-index of 22 and over 3,149 citations across 122 publications.
Metrics
- h-index: 22
- Publications: 122
- Citations: 3,187
Selected Publications
-
How We Do It: Selection of Hidradenitis Suppurativa Lesions for Deroofing Based on Surface Contour (2026)
-
CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting (2025)
Collaboration Network
Top Collaborators
- CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting
Similar Researchers
Based on overlapping research topics